选择性DRD2拮抗剂与ClpP激动剂ONC201在复发性非中线H3 K27M突变胶质瘤队列中的研究
本研究纳入5项试验中接受ONC201治疗的复发性非中线H3 K27M突变弥漫性胶质瘤患者,主要终点为总缓解率。5例脑胶质瘤患者中,研究者报告1例完全缓解和1例部分缓解,盲法独立中心审查按RANO标准确认2例缓解,但其中1例判定为不可测量、另1例为稳定。结论认为ONC201在H3 K27M突变胶质瘤中显示活性,与中枢神经系统位置无关。
要点
- 5例复发性非中线H3 K27M突变弥漫性胶质瘤患者接受ONC201治疗。
- 研究者报告1例完全缓解和1例部分缓解,盲法独立中心审查确认2例缓解。
- 作者结论认为ONC201在H3 K27M突变胶质瘤中显示活性,与中枢神经系统位置无关。
核心结论
- H3 K27M突变弥漫性胶质瘤偶尔发生于非中线大脑,ONC201在H3 K27M突变胶质瘤中显示活性,与中枢神经系统位置无关。
研究设计与样本
- 研究为5项试验中接受ONC201治疗的复发性非中线H3 K27M突变弥漫性胶质瘤患者的队列。
- 入组标准包括按RANO高级别胶质瘤标准可测量病灶、Karnofsky/Lansky体能状态评分≥60、距放疗≥90天。
- 主要终点为总缓解率(ORR)。
主要发现
- 5例脑胶质瘤患者(3例额叶、1例颞叶、1例顶叶)符合入选标准。
- 研究者报告1例完全缓解和1例部分缓解。
- 盲法独立中心审查按RANO标准确认2例缓解,但其中1例判定为不可测量、另1例为稳定。
- 1例缓解患者还报告活动能力和警觉性改善。
关键数值与推荐
- 入组要求Karnofsky/Lansky体能状态评分≥60。
- 入组要求距放疗≥90天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse midline glioma, H3 K27-altered (H3 K27M-altered DMG) are invariably lethal, disproportionately affecting the young and without effective treatment besides radiotherapy. The 2016 World Health Organization (WHO) Central Nervous System (CNS) Tumors Classification defined H3 K27M mutations as pathognomonic but restricted diagnosis to diffuse gliomas involving midline structures by 2018. Dordaviprone (ONC201) is an oral investigational small molecule, DRD2 antagonist, and ClpP agonist associated with durable responses in recurrent H3 K27M-mutant DMG. Activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas has not been reported. METHODS: Patients with recurrent non-midline H3 K27M-mutant diffuse gliomas treated with ONC201 were enrolled in 5 trials. Eligibility included measurable disease by Response Assessment in Neuro-Oncology (RANO) high-grade glioma, Karnofsky/Lansky performance score ≥60, and ≥90 days from radiation. The primary endpoint was overall response rate (ORR). RESULTS: Five patients with cerebral gliomas (3 frontal, 1 temporal, and 1 parietal) met inclusion. One complete and one partial response were reported by investigators. Blinded independent central review confirmed ORR by RANO criteria for 2, however, 1 deemed nonmeasurable and another stable. A responding patient also noted improved mobility and alertness. CONCLUSIONS: H3 K27M-mutant diffuse gliomas occasionally occur in non-midline cerebrum. ONC201 exhibits activity in H3 K27M-mutant gliomas irrespective of CNS location.
引用
- Odia Y, Hall MD, Cloughesy TF, et al. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro Oncol. 2024. PMID: 38386699. doi:10.1093/neuonc/noae021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。